NEW YORK — GenScript Biotech said Wednesday that it has acquired a license to prime editing technology from the Broad Institute.
Prime editing — developed by Broad's David Liu and colleagues — involves directly writing new genetic information into a specified DNA site using a catalytically impaired Cas9 fused to an engineered reverse transcriptase and programmed with a prime editing guide RNA. The RNA specifies the target site and encodes the desired edit.
In late 2021, Liu cofounded a company called Prime Medicine to develop and commercialize the technology for human therapeutic use.
Under the terms of its deal with Broad, GenScript may manufacture and commercialize prime editing components, including nucleases and customized synthetic guides, for use by biopharmaceutical companies in preclinical therapeutic research and development.
Financial and other terms were not disclosed.